Mast Therapeutics Inc (fka MSTX)

[1millman]

29M in the bank. I don't think we will have to worry about a capital raise for a while since they are only burning about 1m per qtr,


ADVENTRX REPORTS THIRD QUARTER FINANCIAL RESULTS



SAN DIEGO - November 8, 2010 - ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX)

today reported financial results for the three and nine months ended September

30, 2010.



"Our balance sheet remains strong due to our commitment to prudent cash

management and reflected $29.3 million in cash at September 30," said Brian M.

Culley, Chief Executive Officer of ADVENTRX. "We recently submitted a New Drug

Application to the FDA for our lead product candidate, Exelbine, as planned,

and look forward to working with the FDA to